Abstract
The pneumococcal polysaccharide vaccine was effective in preventing invasive pneumococcal disease in healthy adults, as well as both culture-confirmed and presumptive pneumococcal pneumonia. The present review offers the best evidence so far on the benefit of the vaccine, which is already recommended for use in industrialized countries for those at risk of pneumococcal infection and its complications. In the resource-limited setting with competing public health priorities, introduction of the polysaccharide vaccine faces several obstacles including the absence of data on disease burden and cost-effectiveness. Pneumococcal polysaccharide vaccine may be offered to those at risk while decisions are made on the best possible strategies for preventing pneumococcal disease in this population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
